ReviewDrugs1997
Clopidogrel.
Review in Drugs, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 165 citations in OpenAlex.
- Clopidogrel and hip fractures, is it safe? A systematic review and meta-analysis.BMC musculoskeletal disorders · 2016Pooled it
- Pharmacodynamic interaction studies of Ginkgo biloba with cilostazol and clopidogrel in healthy human subjects.British journal of clinical pharmacology · 2007Trial
- Recovery of platelet function after discontinuation of clopidogrel treatment in healthy volunteers.British journal of clinical pharmacology · 2001Trial
- Efficacy and safety of indobufen- versus aspirin-based dual antiplatelet therapy following percutaneous coronary intervention: a systematic review and meta-analysis.Annals of medicine and surgery (2012) · 2026Article
- Dual anticoagulant and antiplatelet effects of fructose-1,6-diphosphate in vitro.Scientific reports · 2026Article
- Evaluation of clopidogrel, hypercoagulability, and platelet count in dogs undergoing splenectomy for splenic masses.The veterinary quarterly · 2024Article
- Pharmacogenomic profiling of the South Korean population: Insights and implications for personalized medicine.Frontiers in pharmacology · 2024Article
- Recent Advances in Covalent Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Case report: reuse of tirofiban leads to very severe thrombocytopenia.Frontiers in cardiovascular medicine · 2023Article
- Pleiotropic effects of clopidogrel.Purinergic signalling · 2022Review
- Simultaneous determination of clopidogrel, 2-oxo-clopidogrel, and the thiol metabolite of clopidogrel in human plasma by LC-MS/MS.Journal of biomedical research · 2022Article
- Antithrombotic Therapy: Prevention and Treatment of Atherosclerosis and Atherothrombosis.Handbook of experimental pharmacology · 2022Article
- The Role of Purinergic Signaling in Heart Transplantation.Frontiers in immunology · 2022Review
- Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside.Oxidative medicine and cellular longevity · 2020Review
- Comparison of metabolomics and platelet aggregometry between Plavix and generic clopidogrel in cats: a pilot study.Journal of feline medicine and surgery · 2019Article
- Sulforaphane Inhibits HIV Infection of Macrophages through Nrf2.PLoS pathogens · 2016Article
- Clopidogrel and morphine: Aggregation disturbance?Anatolian journal of cardiology · 2015Article
- Regioselective synthesis of 2-(bromomethyl)-5-aryl-thiophene derivatives via palladium (0) catalyzed suzuki cross-coupling reactions: as antithrombotic and haemolytically active molecules.Chemistry Central journal · 2014Article
- Treatment recommendations to prevent myocardial ischemia and infarction in patients undergoing vascular surgery.Current treatment options in cardiovascular medicine · 2009Article
- Thrombosis in the critically ill neonate: incidence, diagnosis, and management.Vascular health and risk management · 2008Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi. After oral administration, clopidogrel is rapidly absorbed and undergoes metabolic activation in the liver. The principal circulating metabolite is SR 26334, an inactive carboxylic acid derivative. The active metabolite is not yet known. Findings of a large, well controlled study of clopidogrel versus aspirin in patients with atherosclerotic vascular disease (CAPRIE study) indicate that clopidogrel has superior efficacy in terms of prevention of ischaemic stroke, myocardial infarction and vascular death. Clopidogrel-treated patients experienced less frequent gastrointestinal upset, abnormal liver function and gastrointestinal haemorrhage than patients who received aspirin, but more frequent rash and diarrhoea. Neutropenia and thrombocytopenia occurred rarely and at similar rates in both groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.